Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Research & Development (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Research & Development for 4 consecutive years, with $809777.0 as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 13.86% to $809777.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.1 million, a 53.47% decrease, with the full-year FY2024 number at $5.0 million, up 620.84% from a year prior.
  • Research & Development was $809777.0 for Q3 2025 at 60 Degrees Pharmaceuticals, up from $249884.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $3.1 million in Q2 2024 to a low of $27655.0 in Q3 2022.
  • A 4-year average of $567437.8 and a median of $263703.0 in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 1418.27% in 2024, then crashed 91.93% in 2025.
  • 60 Degrees Pharmaceuticals' Research & Development stood at $203457.0 in 2022, then tumbled by 50.75% to $100201.0 in 2023, then soared by 512.72% to $613955.0 in 2024, then surged by 31.9% to $809777.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Research & Development are $809777.0 (Q3 2025), $249884.0 (Q2 2025), and $407622.0 (Q1 2025).